PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24721791-0	2014	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.	CPI203	82-88	delta/notch-like EGF repeat containing	Mus musculus	56-59	
24721791-0	2014	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.	Bortezomib	92-102	delta/notch-like EGF repeat containing	Mus musculus	56-59	
24721791-3	2014	We observed an increased tumorigenicity of bortezomib-resistant MCL cells in vivo, which was associated with plasmacytic differentiation features, like interferon regulatory factor 4 (IRF4) and Blimp-1 upregulation.	Bortezomib	43-53	interferon regulatory factor 4	Mus musculus	152-182	
24721791-3	2014	We observed an increased tumorigenicity of bortezomib-resistant MCL cells in vivo, which was associated with plasmacytic differentiation features, like interferon regulatory factor 4 (IRF4) and Blimp-1 upregulation.	Bortezomib	43-53	interferon regulatory factor 4	Mus musculus	184-188	
24721791-3	2014	We observed an increased tumorigenicity of bortezomib-resistant MCL cells in vivo, which was associated with plasmacytic differentiation features, like interferon regulatory factor 4 (IRF4) and Blimp-1 upregulation.	Bortezomib	43-53	PR domain containing 1, with ZNF domain	Mus musculus	194-201	
24721791-4	2014	Lenalidomide was particularly active in this subgroup of tumors, targeting IRF4 expression and plasmacytic differentiation program, thus overcoming bortezomib resistance.	Lenalidomide	0-12	interferon regulatory factor 4	Mus musculus	75-79	
24721791-5	2014	Moreover, repression of the IRF4 target gene MYC in bortezomib-resistant cells by gene knockdown or treatment with CPI203, a BET (bromodomain and extra terminal) bromodomain inhibitor, synergistically induced cell death when combined with lenalidomide.	Lenalidomide	239-251	interferon regulatory factor 4	Mus musculus	28-32	
24721791-5	2014	Moreover, repression of the IRF4 target gene MYC in bortezomib-resistant cells by gene knockdown or treatment with CPI203, a BET (bromodomain and extra terminal) bromodomain inhibitor, synergistically induced cell death when combined with lenalidomide.	Lenalidomide	239-251	myelocytomatosis oncogene	Mus musculus	45-48	
24721791-6	2014	In mice, addition of CPI203 to lenalidomide therapy further decreased tumor burden, involving simultaneous MYC and IRF4 downregulation and apoptosis induction.	CPI203	21-27	myelocytomatosis oncogene	Mus musculus	107-110	
24721791-6	2014	In mice, addition of CPI203 to lenalidomide therapy further decreased tumor burden, involving simultaneous MYC and IRF4 downregulation and apoptosis induction.	CPI203	21-27	interferon regulatory factor 4	Mus musculus	115-119	
24721791-7	2014	Together, these results suggest that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.	Bortezomib	85-95	interferon regulatory factor 4	Mus musculus	49-53	
24721791-7	2014	Together, these results suggest that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.	Bortezomib	85-95	myelocytomatosis oncogene	Mus musculus	54-57	
24721791-7	2014	Together, these results suggest that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.	Lenalidomide	157-169	interferon regulatory factor 4	Mus musculus	49-53	
24721791-7	2014	Together, these results suggest that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.	Lenalidomide	157-169	myelocytomatosis oncogene	Mus musculus	54-57